Maharashtra deploys ₹1.2-crore machines to check quality of medicines in government hospitals

Spurious and counterfeit medicines are products falsely presented as genuine medicines. They may carry misleading names, labels, or manufacturers. Substandard medicines are genuine or marketed products that fail to meet expected quality, strength, purity, or composition standards. All three categories can make treatment unsafe or ineffective.

The Maharashtra devices are designed to identify suspicious samples among tablets, syrups, and injections. They compare a sample with reference drug constituents stored in the system. A mismatch does not itself prove criminal wrongdoing, but it can signal that a medicine needs formal testing.

This matters because medicines reach patients through several government procurement channels. Maharashtra’s health department will use eight flying squads for random checks at hospitals and clinics. Suspect samples will go to laboratories for confirmation before action is taken against manufacturers or officials. The initiative aims to prevent poor-quality medicines from reaching patients and improve accountability.

Maharashtra purchased eight handheld counterfeit-drug detection machines, each costing ₹1.2 crore. The state also established eight flying squads. Each squad has one machine, allowing teams to carry out checks across government health facilities.

The squads will conduct monthly, random testing rather than relying only on scheduled inspections. Their work covers medicines supplied through the state health system, including drugs bought by Haffkine Bio-Pharmaceutical Corporation, district procurement systems, and local purchases. The machines can examine tablets, syrups, and injections within minutes.

The deployment makes Maharashtra the first state mentioned in the article to introduce this technology. Rajasthan is ordering 116 devices, Madhya Pradesh is expected to take 10, and Jammu and Kashmir is set to get four. The figures show that governments are expanding rapid screening after concerns about spurious medicines, while laboratory tests remain necessary for final verification.

The handheld machine works by matching a medicine sample against reference drug constituents already set in its system. This gives inspectors a rapid preliminary check of whether the sample resembles the expected medicine. The device can test tablets, syrups, and injections.

For example, a flying squad can collect a medicine from a government hospital and place it through the device. The machine compares the sample’s ingredients with the stored reference profile. If the results do not match, the sample is treated as potentially spurious or counterfeit and sent for further examination.

The device is not the final authority on whether a medicine is illegal or defective. The article states that suspect samples must be verified at 12 NABL-recognised testing laboratories. Only after that confirmation can action be taken against a drug manufacturer or government official. This combines quick screening with formal laboratory verification.

A machine can identify a medicine as potentially spurious, counterfeit, or substandard, but its result is only preliminary. The sample must be forwarded for formal verification. This protects the process from treating a rapid screening result as conclusive proof.

The article states that verification will take place at 12 NABL-recognised testing laboratories. If laboratory testing confirms that the medicine is spurious or otherwise defective, the relevant authority can take action. Possible targets include the drug manufacturer and, in some cases, government officials.

The health department’s role is to identify suspicious medicines within its system and forward them to the appropriate authority. Pharmaceutical regulatory enforcement remains under the Food and Drug Administration. The process therefore has two stages: quick detection by flying squads, followed by laboratory confirmation and regulatory action. This is intended to make monitoring more accountable and credible.

Maharashtra’s eight flying squads will conduct monthly, random medicine checks. Each team consists of one qualified pharmacist and one trained government official. Together, they will use the handheld device to screen medicines distributed through the government health system.

Testing will take place at district hospitals, women’s hospitals, clinics, and other government healthcare facilities across Maharashtra. The squads will examine medicines supplied through Haffkine Bio-Pharmaceutical Corporation, the Medical Goods Procurement Authority, district-level procurement systems, and local-level purchases. This covers multiple points where medicines enter the public system.

The health department will identify suspicious drugs and forward samples to the relevant authority. The Food and Drug Administration retains responsibility for pharmaceutical regulatory enforcement. By combining random visits with coverage of several procurement routes, the programme is intended to monitor medicines beyond a single supplier or hospital and strengthen oversight of public distribution.

The handheld devices are screening tools, not the final decision-makers. A result suggesting that a medicine is spurious or counterfeit must be checked before authorities impose consequences. Laboratory confirmation gives the finding a stronger technical and regulatory basis.

The article requires suspect samples to be verified at 12 NABL-recognised testing laboratories. These laboratories provide the formal examination needed to establish whether the sample matches the expected medicine. Only after verification can action be taken against a drug manufacturer or even a government official.

This safeguard also separates detection from enforcement. Flying squads can quickly identify possible problems in hospitals, while the Food and Drug Administration handles pharmaceutical regulatory action. The process is important because a rapid device result can prompt investigation, but formal testing determines whether the medicine truly fails requirements. It supports fair accountability while helping prevent questionable medicines from reaching patients.

Hospitals need more than doctors, buildings, and stocked pharmacies to deliver safe care. The medicines themselves must meet quality expectations. Spurious, counterfeit, or substandard products can undermine treatment even when healthcare facilities have staff and supplies.

Maharashtra’s health minister described medicine quality control as just as critical as doctors, infrastructure, and drug availability. The new squads will test medicines at government hospitals and clinics, including products bought through state, district, and local procurement. Their checks are designed to find problems before questionable medicines reach patients.

The programme also aims to improve transparency, accountability, and regular monitoring in procurement and distribution. Eight squads will carry out monthly random testing, while laboratories will confirm suspicious results. The health department will then forward confirmed cases to the relevant authority, with the FDA responsible for enforcement. Together, these steps strengthen confidence in public healthcare supplies.